CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today announced additional patient data from its ongoing Phase I/IIa clinical study of OpRegen, the Companys retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry age-related macular degeneration (dry AMD), a leading cause of adult blindness in the developed world with no FDA-approved treatment options.
The first Cohort 4 patient treated using both a new subretinal delivery system and the Companys new thaw-and-inject (TAI) formulation of OpRegen has continued to demonstrate notable improvements in vision, having gained 25 readable letters (or 5 lines) 6 months following administration of OpRegen RPE cells, as assessed by the Early Treatment Diabetic Retinopathy Scale (ETDRS). This represents an improvement in visual acuity from a baseline of 20/250 to 20/100 in the treated eye. A second Cohort 4 patient has been similarly dosed, and though early, the patient has shown a small improvement in visual acuity in the treated eye at just 14 days following treatment. To date, improvements have become most evident approximately three to six months after treatment. Both patients had rapid healing at the surgical site with no unexpected complications or any serious adverse events.
We are increasingly optimistic about the data we are collecting in dry AMD, stated Brian M. Culley, CEO of Lineage. We have treated five patients in Cohort 4, those with less advanced disease, which more closely match our intended patient population. At the longest-available assessment point for each patient, all five have shown an increase in the number of letters they can read on an ETDRS eye chart. Importantly, these gains have been maintained for as long as 15 months, which is the longest time point for which we have collected data in the better vision cohort. Notably, the first two patients dosed with the new sub-retinal delivery system by Gyroscope Therapeutics and our innovative TAI formulation of OpRegen had no unexpected complications, so we intend to request the removal of the enrollment treatment stagger from the protocol, which should permit us to significantly accelerate our rate of enrollment. Our objective is to combine the best cells, the best production process and the best delivery system, which we believe will position us as the front-runner in the race to address the unmet opportunity in the potential billion-dollar dry AMD market.
We expect 2020 will be a year of major milestones for Lineage. Based on our existing cash and the current value of our marketable securities, we believe we will be able to achieve these milestones under our reduced 2020 spending plan, continued Mr. Culley.
Having dosed a patient with the combination of Gyroscopes recently 510(k)-cleared Orbit Subretinal Delivery System alongside Lineages new thaw-and-inject formulation of OpRegen RPE cells, I found the procedure to be relatively straightforward, leading to the successful delivery of RPE cells to the subretinal space, stated Judy Ju-Yi Chen, M.D., a retinal surgeon at West Coast Retina, San Francisco, CA. I am hopeful that additional procedures will show that this combination provides superior dose control, safety, and efficacy compared to conventional procedures.
The ETDRS eye chart consists of a set of letters of diminishing size on each line. The more letters a patient can read, the better their vision. The Company also is collecting data on rate of geographic atrophy (GA) growth, best corrected visual acuity (BCVA), low-light visual acuity, reading speed, quality of life questionnaires, microperimetry, and assessing structural changes using optical coherence tomography (OCT), fundus autofluorescence (FAF), and color fundus photography.
About the Phase I/IIa Clinical Study
This is a Phase I/IIa open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with geographic atrophy. The study will enroll approximately 24 patients, divided into 4 cohorts. The first 3 cohorts consisted solely of legally blind patients, with best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort will include approximately 12 patients with vision ranging from 20/250 to as high as 20/64. Cohort 4 also includes patients treated with one of two formulations of OpRegen; the first 3 patients were treated with a formulation which required plating and preparation of cells one day prior to use. The remaining patients on Cohort 4 will be treated with an off-the-shelf or thaw-and-inject formulation of OpRegen which can be shipped directly to sites and used immediately upon thawing, which removes the complications and logistics of having to use a dose preparation facility. Staggered intervals within and between cohorts are applied to ensure patient safety and welfare. The primary objective of the Phase I/IIa study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. Additionally, for the patients in Cohort 4 that receive subretinal delivery of OpRegen utilizing Gyroscope Therapeutics Orbit Subretinal Delivery System (Orbit SDS), objectives will include the evaluation of the safety of delivery of OpRegen using the Orbit SDS.
About OpRegen
OpRegen is a retinal pigment epithelium (RPE) transplant therapy in Phase I/IIa development for the treatment of dry AMD, a leading cause of adult blindness in the developed world. OpRegen consists of a suspension of RPE cells delivered subretinally as an intraocular injection. RPE cells are essential components of the back lining of the retina and function to help nourish the retina including photoreceptors. OpRegen has been granted Fast Track designation from the U.S. Food and Drug Administration. OpRegen is a registered trademark of Cell Cure Neurosciences Ltd., a majority-owned subsidiary of Lineage Cell Therapeutics, Inc.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineages programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineages clinical assets include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia, a facial aesthetics product that was recently granted a Conformit Europenne (CE) Mark. For more information, please visit http://www.lineagecell.com or follow the Company on Twitter @LineageCell.
Forward-Looking Statements
Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as believe, may, will, estimate, continue, anticipate, design, intend, expect, could, plan, potential, predict, seek, should, would, contemplate, project, target, tend to, or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to the development of Lineages OpRegen program, as well as Lineages spending plans. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineages actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineages business and other risks in Lineages filings with the Securities and Exchange Commission (the SEC). Lineages forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading Risk Factors in Lineages periodic reports with the SEC, including Lineages Annual Report on Form 10-K filed with the SEC on March 14, 2019 and its other reports, which are available from the SECs website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
- WHO launches new initiative to tackle the main cause of vision impairment - December 19th, 2024
- Blindness Advocates on Why There Should Be Audio Description Oscars - Variety - December 19th, 2024
- Diabetic retinopathy is treatable and preventable but only if you catch it in time - USA TODAY - December 19th, 2024
- AI: Could it help prevent blindness in diabetics? - BBC.com - December 19th, 2024
- Health Officials Investigate Rare Form of Blindness Tied to Ozempic - Gizmodo - December 19th, 2024
- Ozempic Could Be Blinding People Trying to Lose Weight - VICE - December 19th, 2024
- What is retinitis pigmentosathe vision disorder in the movie Blink? - National Geographic - December 19th, 2024
- VR shows promise in aiding navigation of people with blindness or low vision - Health Tech World - December 19th, 2024
- Ozempic could be linked to a common cause of sudden blindness, study finds - Quartz - December 19th, 2024
- New virtual realitytested system shows promise in aiding navigation of people with blindness or low vision - Tech Xplore - December 19th, 2024
- Ex-meth user who gouged her own eyeballs out while high says she is happier years after nightmarish episode - New York Post - December 19th, 2024
- Officials investigating link between Ozempic and eye-rotting disease that makes people blind - Daily Mail - December 19th, 2024
- Youngster to 'have eye removed' after minor fall - but NHS waitlist 'over 3 years' - NationalWorld - December 19th, 2024
- Restoring Vision: The Promise of Stem Cells in Healing Blindness - This is Local London - December 19th, 2024
- COAVS and Fred Hollows Foundation strengthen efforts to combat blindness in Pakistan - 24newshd - December 19th, 2024
- Study finds link between Ozempic and increased risk of vision loss - The Express Tribune - December 19th, 2024
- Going blind at 33 is devastating I wont see my childrens faces as they grow up - The Telegraph - December 19th, 2024
- Europol terror report reveals stark blindness about where the danger lies - Gript - December 19th, 2024
- Elton John lost his vision; signs and symptoms of eye infections that can cause blindness - The Times of India - December 6th, 2024
- Elton John's battle with blindness: How 77-year-old star's husband David Furnish guided him around premiere as - Daily Mail - December 6th, 2024
- Experimental study shows connection between COVID infection and age-related blindness - Medical Xpress - December 6th, 2024
- Elton John confirms shocking blindness after severe infection fight: I havent been able to see.. - Hindustan Times - December 6th, 2024
- Yes, an Eye Infection *Can* Lead To Vision Loss Heres How - Katie Couric Media - December 6th, 2024
- Elton John Battling Partial Blindness After Serious Eye Infection - Digital Music News - December 6th, 2024
- CU Anschutz researchers working to cure blindness through total eye transplantation - 9News.com KUSA - December 6th, 2024
- Elton John lost his vision from an eye infection. Here's why that might happenand how to prevent it - Fortune - December 6th, 2024
- Elton John announces blindness due to infection - CBS19.tv KYTX - December 6th, 2024
- David Frost: I suffer from face blindness. As a politician, being unable to identify people is agony - The Telegraph - December 6th, 2024
- Hes still standing how Elton John has survived far worse than blindness - The Telegraph - December 6th, 2024
- Foundation Fighting Blindness Partners with University of Colorado Anschutz Medical Campus and Other Leading Institutions to Secure Up to $46 Million... - December 6th, 2024
- Walmart helping low vison and blind customers shop with new app - KSLA - December 6th, 2024
- Elton John Says He Is Blind In The Right Eye Due to An Infection; What Is It All About? - Times Now - December 6th, 2024
- Trumps Win: The Blindness of Republicans and Democrats - The Times of Israel - December 6th, 2024
- Heres every song on The Agency soundtrack - NME - December 6th, 2024
- Elton John's worrying health battles in full as he confirms blindness - The Mirror - December 6th, 2024
- Symptoms of serious eye infections after Elton John says he is now blind - LADbible - December 6th, 2024
- Shocking! Elton John Reveals Blindness After Severe Eye Infection: Havent Been Able To... - Republic World - December 6th, 2024
- Face blindness will be examined as part of new project - BBC - December 6th, 2024
- Make your Word documents accessible to people with disabilities - November 27th, 2024
- Make your Word documents accessible to everyone with Accessibility ... - November 27th, 2024
- Use color and contrast for accessibility in Microsoft 365 - Microsoft ... - November 27th, 2024
- Accessibility tools for Word - Microsoft Support - November 27th, 2024
- Rules for the Accessibility Checker - Microsoft Support - November 27th, 2024
- Everything you need to know to write effective alt text - November 27th, 2024
- Create or edit a hyperlink - Microsoft Support - November 27th, 2024
- Video: Check the accessibility of your document - Microsoft Support - November 27th, 2024
- Woman lives with unique condition that means she can still see where things are despite being blind - LADbible - November 27th, 2024
- Arrogance and inherent blindness: Civil probe slams Netanyahu for Oct. 7 failures - The Times of Israel - November 27th, 2024
- Are pistachios the secret to preventing blindness as you age? - The Times of India - November 27th, 2024
- AI is helping people with blindness navigate the world around them - Spectrum News 1 - November 27th, 2024
- Unraveling the Mysteries of Cerebral/Cortical Visual Impairment | Newswise - Newswise - November 27th, 2024
- The silent struggles of color blind students in the UK - News-Medical.Net - November 27th, 2024
- An ideal way to treat Indias corneal blindness problem - The Hindu - November 27th, 2024
- Elle Fanning Has Blush Blindness (and She's Not Afraid to Say It!)This $13 Product Is Key - Who What Wear - November 27th, 2024
- This simple nut is the key to fighting age-related blindness - The Economic Times - November 27th, 2024
- Morning Open Thread: To Lose in Ignorant Blindness What We Might Hold Fast - Daily Kos - November 27th, 2024
- The Murder Capital confirm details of third album Blindness - DIY Magazine - November 27th, 2024
- World report on vision - World Health Organization (WHO) - November 16th, 2024
- Eye care, vision impairment and blindness programme - November 16th, 2024
- $45,000 Raised to benefit SGML Eye Hospital near Ujjain, India for rural and underserved population to prevent blindness - The Indian Panorama - November 16th, 2024
- Foundation Fighting Blindness Funds 35 New Research Grants in FY2024, Renames Key Program to Honor Former Board Chair - PR Newswire - November 16th, 2024
- Fighting blindness with Love Tags - WFLA - November 16th, 2024
- Woman With Rare Disease Waiting For Blindness To 'Cure' Hallucinations - News18 - November 16th, 2024
- Color Blindness Market Is Anticipated To Grow In A Promising - openPR - November 16th, 2024
- Towards a truer vision of broader inclusivity - The New Indian Express - November 16th, 2024
- WHO launches first World report on vision - October 22nd, 2024
- Eye health, vision impairment and blindness - World Health Organization ... - October 22nd, 2024
- Onchocerciasis - World Health Organization (WHO) - October 22nd, 2024
- Eye care, vision impairment and blindness: Refractive errors - October 22nd, 2024
- Blindness Prevention and Control - World Health Organization (WHO) - October 22nd, 2024
- Onchocerciasis (river blindness) - World Health Organization (WHO) - October 22nd, 2024
- Trachoma - World Health Organization (WHO) - October 22nd, 2024
- Blindness is not a curse to be broken - America: The Jesuit Review - October 22nd, 2024
- Alfred University gives away two pairs of EnChroma glasses for color blindness - www.alfred.edu - October 22nd, 2024
- All the Plants We Cannot See - The Revelator - October 22nd, 2024
- ASI Power Summit 2024: How Blindness Helped Michael Hingson Survive the 9/11 Attacks - ASI - October 22nd, 2024
- People with blindness and their allies rally outside Uber and Lyft over ride denials - The Mercury News - October 22nd, 2024
- New Study Links Ozempic to BlindnessBut They Can Actually Protect Your Eyes - First For Women - October 22nd, 2024
- Conservatives Use Trump Assassination Attempt to Target Women in Anti-Diversity War - The American Prospect - October 22nd, 2024
- Google AI to help detect preventable blindness in India and Thailand - Techloy - October 22nd, 2024